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Abstract
Background: In the early phases following heart transplantation a main challenge is to reduce the impact of acute
rejections. Previous studies indicate that intracellular ciclosporin A (CsA) concentration may be a sensitive acute rejection
marker in renal transplant recipients. The aims of this study were to evaluate the relationships between CsA
concentrations at different target sites as potential therapeutic drug monitoring (TDM) tools in heart transplant recipients.
Methods: Ten heart transplant recipients (8 men, 2 women) on CsA-based immunosuppression were enrolled in this
prospective single-center pilot study. Blood samples were obtained once to twice weekly up to 12 weeks post-transplant.
One of the routine biopsies was allocated to this study at each sampling time. Whole blood, intralymphocyte, and
endomyocardial CsA concentrations were determined with validated HPLC-MS/MS-methods. Mann–Whitney U test was
used when evaluating parameters between the two groups of patients. To correlate whole blood, intralymphocyte, and
endomyocardial CsA concentrations linear regression analysis was used.
Results: Three patients experienced mild rejections. In the study period, the mean (range) intralymphocyte CsA trough
concentrations were 10.1 (1.5 to 39) and 8.1 (1.3 to 25) ng/106 cells in the rejection and no-rejection group, respectively
(P=0.21). Corresponding whole blood CsA concentrations were 316 (153 to 564) and 301 (152 to 513) ng/mL (P=0.33).
There were no correlations between whole blood, intralymphocyte, or endomyocardial concentrations of CsA (P >0.11).
Conclusions: The study did not support an association between decreasing intralymphocyte CsA concentrations and
acute rejections. Further, there were no association between blood concentrations and concentrations at sites of action,
potentially challenging TDM in these patients.
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Background
Heart transplantation is the final treatment option in end-
stage heart failure and even though the procedure shows
good results there is still room for improvement. In the
early post-transplant phase a main challenge is to reduce
the impact of acute rejections. The negative effects of the
immunosuppressive therapy used to avoid acute rejection
is however also a challenge in these patients. Hence, in the
early phases following transplantation a combination of
therapeutic drug monitoring (TDM) of immunosuppressive
drugs and weekly endomyocardial biopsies are used to
optimize the treatment for heart transplant recipients. A
method with high specificity and accuracy to prevent graft
rejection is an unmet clinical need.
Ciclosporin A (CsA) has been a cornerstone in the im-
munosuppressive therapy since its introduction in the mid
1980s. CsA is metabolized by the cytochrome P-450 3A
(CYP3A) subfamily to >30 more or less pharmacologically
active metabolites [1]. In addition, CsA is both a substrate
and an inhibitor of the efflux transporter P-glycoprotein
(P-gp) [2]. P-gp, coded by the ABCB1 gene, is expressed in
T-lymphocytes and transports CsA out of the cell [2-4]. A
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previous study has shown that polymorphism in the
ABCB1 gene may influence the intralymphocyte CsA con-
centration [5]. These pharmacokinetic properties are the
basis for the substantial intra- and interindividual variation
in CsA concentration. CsA is associated with a numerous
of severe side effects, resulting in a narrow therapeutic
range which makes the TDM of the drug extra demanding.
The current routine TDM of CsA is performed by measur-
ing whole blood concentrations, either in trough samples
or lately also in C2 samples. However, since CsA exerts its
immunosuppressive effect within T-lymphocytes [6], meas-
urement of CsA within these cells may provide more rele-
vant information regarding the immunosuppressive effect
of CsA than whole blood concentrations. Several groups
have shown data that support this hypothesis in transplant
recipients [5,7-10]. We have recently shown that intracellu-
lar CsA concentration in T-lymphocytes decreased several
days before an acute rejection was possible to diagnose in
renal transplants by current standard clinical methods [7].
Intracellular CsA concentration monitoring therefore
seems to have a potential as a semi-invasive method for
prediction of acute rejection episodes. The purpose of the
study was to evaluate the relationships between CsA con-
centrations at different target sites, that is whole blood,
lymphocytes, and endomyocardial tissue, and to investigate
CsA concentrations in isolated T-lymphocytes from heart
transplant recipients in order to further examine intracellu-
lar monitoring as a potential TDM tool. In addition, the
patients’ genotype of P-gp was determined to investigate if
genetic polymorphism in the ABCB1 gene could explain
differences in the intralymphocyte concentration of CsA.
Patients and methods
Patients and study design
Ten heart transplant recipients (8 men and 2 women) with
a mean age of 52 ± 12 years were enrolled in this single-
center prospective pilot study. The patients were included
17 ± 6 days after transplantation and followed for a period
of 70 ± 8 days. They all applied to standard post-transplant
procedures at Oslo University Hospital, Rikshospitalet. All
the patients were treated with C0-monitored CsA, my-
cophenolate mofetil (MMF), and steroids according to the
center immunosuppressive protocol at that time. The CsA
treatment was initiated with 10 mg/kg orally on the day of
transplantation followed by C0 monitoring with target con-
centrations of 250 to 350 ng/mL after 1 month and further
tapered to 60 to 120 mg/mL after 1 year of treatment. All
patients received 1.5 g MMF twice daily from the day of
transplantation, the doses was further adjusted according
to side effects. The patients received 0.2 mg/kg/day oral
prednisolone from the second postoperative day and were
further tapered to 0.1 mg/kg/day within the following
months. None of the patients were given induction
therapy. Patients were not allowed to use concomitant
drugs that could interact with CsA pharmacokinetics.
Study specific whole blood samples (EDTA vacutainer
tubes) for CsA analyses and T-lymphocyte isolation were
taken in association with routine blood samples for stand-
ard clinical follow-up; twice weekly during the first weeks
and thereafter weekly samples for the rest of the inves-
tigation period. Whole blood samples and isolated T-
lymphocytes were frozen and stored at −20°C until analysis.
Routine monitoring of these patients include series of six
endomyocardial biopsies at post-transplant week 1, 2, 5, 7,
10, and 12. One of the six biopsies taken at each time-point
was allocated for CsA analysis in this study. The biopsy was
wrapped in a piece of aluminum foil and stored at −20°C
until analysis. In addition, EDTA whole blood was drawn
once during the study for determination of the recipients
ABCB1 (1199G>A, 1236C>T, 2677G>A, 2677G>G, and
3435C>T) and CYP3A5 (*3 (6986A>G, splicing defect))
genotypes. All acute rejections were verified with a biopsy
and classified according to the International Society for
Heart and Lung Transplantation (ISHLT) standardized car-
diac biopsy grading [11,12].
The study was performed in accordance with the Dec-
laration of Helsinki, local laws, and other regulations,
and all patients signed a written informed consent before
study start. The study was evaluated by the Regional
Committee for Medical Research Ethics and approved
by the Norwegian Medicines Agency. The study is regis-
tered on ClinicalTrials.gov (NCT00139009).
T-lymphocyte isolation
T-lymphocytes were isolated from freshly drawn heparin
whole blood using PrepacyteW (BioE, St Paul, MN, USA)
[13]. An aliquot of 100 μM of verapamil was pre-added to
the heparin vacutainers to inhibit P-gp from pumping CsA
out of the cells [14]. PrepacyteW uses a negative selection
process and facilitates the agglutination and precipitation of
erythrocytes, B-lymphocytes, and mature myeloid cells like
granulocytes, monocytes, and platelets, producing a super-
natant of lymphocytes, highly enriched for T-cells. The ex-
cess of erythrocytes in the supernatant was removed by
lysis using Vitalyse™. After centrifugation (400 g) and wash-
ing, the remaining supernatant contains >97% lymphocytes
comprising 88% to 96% of the resultant cell population
[15]. To relate the intracellular concentration to a physio-
logical parameter, cell count using a Bürker Chamber was
performed. The cells were isolated within 4 h post sam-
pling. The isolating method starts with 7 mL of whole
blood and produces a T-lymphocyte isolate pellet to which
was finally added 1 mL methanol:ACN:water (1:1:3) for cell
lysis and protein precipitation. The mixture was stored
at −20°C until solid phase extraction and subsequent ana-
lysis of CsA concentrations.
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CsA and metabolite concentrations
Concentrations of CsA and six of its main metabolites
were determined in whole blood, intracellularly in isolated
T-lymphocytes, and in endomyocardial biopsies. The whole
blood and intracellular CsA and metabolite concentrations
were determined with a validated high-performance liquid
chromatography-tandem mass spectrometry (HPLC-MS/
MS) method previously described [16]. In brief, the
analytes were extracted and purified by protein precipita-
tion with methanol and centrifugation before the superna-
tants were subjected to solid phase extraction using Oasis
hydrophilic-lipophilic balance cartridges. CsA and metabo-
lites were separated chromatographically on a C8-colum
before MS/MS detection. The intracellular concentration
of CsA was related to the number of T-lymphocytes in the
sample (ng/106 cells).
The concentration of CsA and two metabolites, AM1
and AM9, were determined in endomyocardial biopsies by
using a modification of the method described above [16].
After moistening the biopsy with 20 μL water for 5 min,
the biopsy was weighed before homogenized in 150 μL de-
ionized water with an automated tissue homogenizer;
PrecellysW 24 (Bertin Technologies, France), programmed
to 2×50 s cycles with a 20-s pause. Fifty μL of the internal
standard (0.5 μg/mL ciclosporin C (CsC) in methanol:
acetonitrile (ACN): water (1:1:3)) was added to 100 μL
homogenate and this mixture was protein precipitated
with 100 μL ACN. Particulate matter was removed by cen-
trifugation (30 min, 12,000 g, 4°C) and the supernatant
was evaporated to dryness under a stream of nitrogen gas.
The eluate was reconstituted in 50 μL of 65% mobile
phase A consisting of ACN/20 mM ammonium formate
buffer (NH4
+COO-) pH 3.6 (20:80 v/v), and 35% mobile
phase B, consisting of ACN/ NH4
+COO- (80:20 v/v), before
injecting 20 μL on the LC-MS/MS system. The analytical
system consisted of Aquity ultra performance liquid chro-
matography™ (UPLC) connected to a Micromass Quattro
micro™ triple quadrupole mass spectrometry (MS) de-
tector (Waters Corporation, USA) using electrospray
ionization (ESI) interface. The detector was operated in a
positive ion mode. Separation of the analytes was carried
out on a reversed phase UPLC C18 column (100 × 2.1
mm, 1.7 μm) (Acquity UPLC BEH Shield C18, Waters,
USA) and the column was heated to 70°C. The analytes
were eluated using a stepwise gradient at the flow rate of
0.6 mL/min. The gradient program was as follows: 62%
mobile phase A for 14 min followed by a gradually in-
crease of mobile phase B to 100% for 7 min. One hundred
per cent mobile phase B was held constant for 10 min and
the system was finally re-equilibrated at start conditions
for 5 min. Analysis run time per sample was 36 min. Cali-
bration curves were produced from stock solutions of
CsA, AM1, and AM9, which were mixed with the internal
standard (CsC), evaporated to dryness under a stream of
nitrogen gas and reconstituted in 65% mobile phase A and
35% mobile phase B. All standard curves comprised of at
least eight concentration levels, including a blank sample
(0.0 to 80 ng/mL). The regression coefficients (r2) of the
linear standard curves were >0.998 and for both CsA and
the metabolites the validation parameters for precision
and accuracy (intra- and inter-run) were <9%.
Genotyping
Genotyping was performed as previously described,
using a polymerase chain reaction (PCR) - restriction
fragment length polymorphism assay [17]. Restriction
enzyme digestion generated DNA fragments that were
separated by electrophorese on 3% agarose gels. All the
patients were screened for relevant polymorphism in
CYP3A5 (*3 (6986A>G, splicing defect)) and ABCB1
(1199G>A, 1236C>T, 2677G>T, 2677G>A, 2677G>G,
and 3435C>T). Dr D Katz (Abbott Laboratories, Abbot
Park, IL (MDR1)) and Dr R van Schaik (Department of
Clinical Chemistry Erasmus MC, The Netherlands
(CYP3A5)) kindly supplied positive controls.
Statistics and calculations
Mann–Whitney U test was used when evaluating pa-
rameters between the two groups of patients. To correl-
ate whole blood, intralymphocyte, and endomyocardial
CsA concentrations linear regression analysis was used.
Statistical significant differences were considered for
P values <0.05. All statistical analyses were performed
using SPSS version 19. The renal function was estimated
using the Modification of Diet in Renal Disease (MDRD)
formula [18,19].
Results
Patients
All 10 heart transplant recipients completed this 3-month-
long pilot study. Three patients experienced biopsy-proven
acute rejection episodes during the study at an average of
58 ± 16 days after transplantation, and one of these patients
experienced in total three rejection episodes during the
study period. One of the patients in the no-rejection group
developed renal failure during the study. Demographic data
at inclusion are summarized in Table 1. No significant dif-
ferences were observed between the rejecting and the no-
rejection patients.
Intracellular T-lymphocyte and whole blood
concentrations of CsA
An average of 12.3 (range, 7 to 20) samples per patient
was analyzed for both intracellular and whole blood con-
centration of CsA. In total, 139 whole blood samples and
121 intralymphocyte samples was analyzed during the
study period. Both intracellular and whole blood concen-
trations of CsA showed large intra- and interindividual
Robertsen et al. Transplantation Research 2013, 2:5 Page 3 of 8
http://www.transplantationresearch.com/content/2/1/5
variations in both groups, and there were no correlation
between whole blood and intracellular CsA concentration
throughout the study (r2=0.012, P=0.11; Figure 1). In the
study period, the mean (range) intracellular CsA trough
concentrations were 10.1 (1.5 to 39) and 8.1 (1.3 to 25)
ng/106 cells in the rejection and no-rejection groups, re-
spectively (P=0.21). The corresponding mean (range)
whole blood CsA concentrations were 316 (153 to 564)
and 301 (152 to 513) ng/mL, respectively (P=0.33).
Figure 2 shows the individual ratio of whole blood to
intralymphocytic CsA concentration for the three patients
experiencing rejection and for the mean ratios for the no-
rejection patients during the study period. One of the re-
jection patients (patient 21) showed an increase in the
whole blood/intracellular ratio at time of rejection, due to
a combination of declined intracellular concentration and
a slight increase in the whole blood concentration. In the
two other rejection patients (patients 25 and 29) no change
was observed in the whole blood/intracellular ratio in con-
junction to the rejection episode, but interestingly patient
25 showed substantially increased ratio on several occa-
sions prior to the rejection episode as compared to the
mean ratio for the no-rejection group (Figure 2A). In the
no-rejection group the mean individual whole blood/intra-
cellular ratio ranged from 33.6 to 86.4 with a correspond-
ing standard deviation range of 17.8 to 46.7. The absolute
average intracellular CsA concentration to the time of re-
jection was 10.4 (1.5 to 39) ng/106 cells in the rejection
group and the corresponding average CsA concentration
to the mean time of rejection (day 58) was 8.2 (1.3 to 25)
ng/106 the no-rejection group (P=0.38). At the rejection
day the absolute intracellular CsA concentration for the
three rejecting patients were 9.4, 7.2, and 18. 4 ng/106 cells.
CsA metabolites, genotypes, and renal function
Genotyping results for both ABCB1 (1199G>A, 1236C>T,
2677G>T, 2677G>A, 2677G>G, and 3435G>T) and
CYP3A5 (*3) are presented in Table 2. Two out of three
patients in the rejection group were homozygote ABCB1
TTTcarriers, but all patients were potential carriers of this
reduced P-gp function haplotype. Three of the 10 patients
expressed functional CYP3A5 enzymes (CYP3A5*1), one
in the rejection group. It was observed that the patients
expressing functional CYP3A5 enzymes tended to have
higher concentrations of the metabolites AM19 (P=0.21),
AM1c9 (P=0.57), AM1c (P=0.73), AM4N (P=0.27), similar
concentration of AM9 (P=0.43), and a decreased concen-
tration of AM1 (P=0.57) compared to the patients without
functional CYP3A5 (Figure 3). We did not observe a sig-
nificant difference in renal function between patients ex-
pressing functional CYP3A5 (eGFR of 51 ±23 mL/min)
and patients not expressing functional CYP3A5 (eGFR of
66 ±19 mL/min, P=0.38). One of the three patients
Table 1 Demographic data at time of inclusion
All No-rejection group Rejection group P value
Gender (male/female) 8/2 2/5 3/0 -
Weight (kg) 76.7 ± 18.0 73.9 ± 19.5 83.3 ± 15.0 0.517
Age (years) 51.9 ± 11.9 51.0 ± 12.9 54.0 ± 11.5 0.833
CsA dose (mg/day) 330 ± 115 293 ± 116 417 ± 57.7 0.183
CsA C0 (ng/mL) 245 ± 59.3 239 ± 71.7 257 ± 10.4 0.383
Plasma creatinine (μmol/L) 131 ± 55 146 ± 59.8 96.5 ± 16.5 0.117
Creatinine clearance (mL/min) 58.0 ± 21.4 50.3 ± 18.9 77.6 ± 14.7 0.067
Serum urea (mmol/L) 10.5 ± 5.3 10.8 ± 6.0 9.8 ± 3.8 1.000
Hematocrit (%) 32.3 ± 4.2 32.3 ± 4.9 32.5 ± 0.7 0.500
Steroid dose (mg/day) 14.8 ± 3.8 13.6 ± 3.7 17.5 ± 2.5 0.137
Treated with MMF 10/10 7/7 3/3 -
Data are means ± SD. All variables were analyzed with a Mann–Whitney U test.
CsA, cyclosporine A; MMF, mycophenolate mofetil.
Figure 1 Correlation between whole blood and intracellular
CsA concentration in individual patients. The figure shows all the
whole blood and intracellular samples (n = 120) obtained during
the study.
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expressing functional CYP3A5 experienced renal failure
during the study period.
Concentration of CsA and metabolites in endomyocardial
biopsies
Nineteen biopsies, from seven out of the 10 patients, were
obtained for the current study. Only one out of these seven
patients was in the rejection group. In these patients an
average of 2.7 (range, 1 to 6) biopsies per patient were ana-
lyzed for concentrations of CsA and two metabolites, AM1
and AM9. CsA concentration varied from 216 to 833 pg/
mg heart tissue. No correlations were found between
endomyocardial CsA concentrations and whole blood
(r2=0.029, P=0.48) or intralymphocyte concentrations
(r2=0.055, P=0.35). There was no obvious association be-
tween the endomyocardial concentration of CsA and rejec-
tion episodes.
Discussion
The present pilot study does not support the hypothesis of
decreased intracellular T-lymphocyte concentration of
CsA prior to rejection episodes. The main finding, how-
ever, was that there were no correlations between CsA
Figure 2 The ratio (± SEM) of whole blood to intralymphocytic CsA trough concentration days after transplantation. (A) The CsA whole
blood/intracellular ratio (± SEM) for the three rejection patients. The arrows mark the point where the patients experienced an acute rejection
episode. High levels of the ratio represent a drop in intracellular CsA concentration compared to whole blood concentration. (B) The mean whole
blood/intracellular ratio (± SEM) for the patients with no rejection.
Table 2 Patient’s genotyping of ABCB1 and CYP3A5
Patient ABCB1 CYP3A5
2677G>A/T 1236C>T 3435C>T *3
21 T/T T/T T/T *3/*3
22 G/T C/T C/T *1/*3
23 G/T C/T C/T *3/*3
24 G/T C/T C/T *3/*3
25 G/T C/T C/T *3/*3
26 T/T T/T T/T *3/*3
27 G/T C/T T/T *1/*3
28 G/T C/T T/T *3/*3
29 T/T T/T T/T *1/*3
30 G/T C/T T/T *3/*3
Figure 3 Ratio between the mean concentration of the
metabolites AM19, AM1c9, AM1, AM9, AM1c, and AM4N in
patients with CYP3A5*1/3 and in patients with CYP3A5*3/*3.
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concentrations in whole blood, T-lymphocytes, or endo-
myocardial tissue.
Gustafsson and colleagues are, to our knowledge, the
only group who previously has measured intralymphocyte
CsA concentration in heart transplant recipients [10]. The
study discovered a close association between whole blood
CsA C2 concentrations and lymphocyte CsA AUC0-12 in
MMF treated patients. This is contradictory to our find-
ings where no correlation between CsA in whole blood
and T-lymphocytes was found. A possible explanation to
this discrepancy could be the fact that Gustafsson et al.
performed measurement of whole blood CsA concentra-
tion in C2 samples and determined lymphocyte CsA
AUC0-12, while in the present study CsA concentration
were measured in C0 samples. C2 monitoring leads to an
improvement in the clinical outcomes in heart transplant
recipients [20,21] and measuring whole blood C2 concen-
trations could perhaps more precisely predict the CsA
concentration and, in turn AUC, within lymphocytes.
Nevertheless, our results are in agreement with previous
studies reporting of no correlation between CsA concen-
tration in whole blood and lymphocytes [22,23]. Although
these studies were performed in different patient popula-
tions (renal transplant recipients and healthy volunteers),
the findings demonstrate that whole blood CsA concen-
trations may not be a good predictor of the target site con-
centration of CsA. To the best of our knowledge, the
present pilot study is the first to report of CsA concentra-
tion in endomyocardial tissue and to show the absence of
correlation with both whole blood and intralymphocyte
CsA concentrations in heart transplant recipients. In a
recent study, Capron et al. evaluated the correlation
of intrahepatic, peripheral mononuclear cells (PBMC)
and blood concentrations of tacrolimus (Tac), another
calcineurin inhibitor, in liver transplant recipients. In this
study, no correlation was found between mean Tac blood
concentration and PBMC or intrahepatic concentration of
Tac. However, it was discovered that intrahepatic Tac con-
centration significantly correlated with Tac PBMC concen-
trations [24]. Capron et al. have earlier showed that
hepatic tissue concentrations of Tac correlated with early
acute rejection after liver transplantation, this in contrast
to blood concentrations [25]. These findings also suggest
that direct drug measurement at the target sites (lympho-
cytes and graft tissue) could be a better approach than
measuring whole blood concentration to predict the effi-
cacy of immunosuppressive drugs.
The present pilot study failed to show correlation be-
tween intracellular CsA concentration in T-lymphocytes
and acute rejection episodes. Several other groups have
however shown a possible correlation between low intra-
cellular CsA concentration and rejection episodes in renal
transplant recipients. A study conducted by Barbari et al.
demonstrated that rejecting patients exhibited a low CsA
lymphocyte content despite a higher or similar CsA blood
concentration [8]. Similarly, we have shown that renal
transplant recipients experiencing a rejection episode had
a lower intracellular exposure of CsA several days before
clinical diagnosis of acute rejection episodes [7]. The dif-
ference observed between renal and heart transplant re-
cipients in this respect have no obvious explanation.
However, as mentioned before C2 concentrations are
known to correlate better with acute rejections compared
to trough concentrations [20] and it was C2 concentra-
tions that were used in our previous study [7]. Further, it
cannot be ruled out that the renal transplant recipients ex-
periencing an acute rejection episode had a stronger im-
mune response compared to rejecting patients in the
present study.
Since CsA is both a substrate and an inhibitor of P-gp,
the patients’ genotype for this efflux pump was deter-
mined as it is expressed in T-lymphocytes. The ABCB1
haplotype TTT (1236T, 2677T and 3435T) has previ-
ously been associated with impaired functional transport
activity [26]. In the present study only three patients ex-
perienced an acute rejection episode. Two of the three
rejection patients were homozygote ABCB1 TTT haplo-
types, but all patients included in the study were poten-
tial TTT haplotypes. This makes the interpretation of
the data difficult, but if the hypothesis that acute rejec-
tion episode are associated with lower intracellular CsA
concentrations should hold true, it would be expected
that rejection patients have high transport activity of P-gp,
contradictory to our findings [7,27].
Renal failure is a frequent and recognized complica-
tion following heart transplantation and CsA has been
implicated as a potential risk factor [28-31]. Previous
studies indicate that elevated blood and urine concentra-
tions of the secondary metabolites AM19, AM1c, and
AM1c9 may be associated with renal dysfunction in CsA
treated patients [31-35], and that CYP3A5 expressers
have higher formation of the secondary metabolites
AM19 and AM1c9 [36]. Contrary, in renal transplant re-
cipients on Tac-based immunosuppression, a protective
role of CYP3A5 expression in the kidney has been ob-
served [37]. By contrast to previous findings [31-35,38],
the present study did not show any tendencies of a re-
duced renal function by an increased concentration of
the secondary metabolites or functional CYP3A5 geno-
types. This should however be carefully interpreted as
the power is relatively low as outlined below.
Study limitations
The main limitation of this pilot study is the low sample
size and only three patients experienced acute rejection
episodes. This clearly limits the conclusion that could
be drawn. In addition, CsA concentrations were mea-
sured in trough samples and not in C2 samples. The
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intralymphocyte CsA concentration displayed a high
intra- and interindividual variation, and this could
partly be explained by the complex isolation procedure
and the low level of automatization of the T-lymphocyte
isolation method.
Conclusions
The main finding of the present pilot study was that no
correlation between CsA concentrations in whole blood,
T-lymphocytes or endomyocardial tissue was present in
heart transplant recipients. In addition, results from the
present study do not support previous findings that CsA
concentrations within T-lymphocytes decrease days be-
fore acute rejection episodes are diagnosed. The small
sample size clearly limits the extent to which any defini-
tive conclusion could be drawn. However, both findings
are relevant with regards to TDM of CsA in this popula-
tion and should be further investigated in properly
powered clinical trials.
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